Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection

Upper Respiratory Tract Infection Clinical Trial

Official title:

A Two-Treatment, Sequential, Crossover Study of the Pharmacokinetics of Adrenaline After Administration of ARS -1 in Subjects With Upper Respiratory Tract Infection (Infectious Rhinitis)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04930900
• Other study ID #: EPI 014
• Status: Completed
• Phase: Phase 1
• Start date: August 9, 2021
• Est. completion date: July 25, 2022

Study information

• Verified date: July 2022
• Source: ARS Pharmaceuticals, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, single-dose, two-period study that will consist of a combined screening and baseline period and an open-label treatment period. Subjects will be enrolled when they experience an Upper Respiratory Tract Infection with nasal congestion and edema.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 15
• Est. completion date: July 25, 2022
• Est. primary completion date: March 31, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria:

• Treatment Period 1 only, subject has symptoms of an URTI at time of dosing based on the clinical judgement and the positive infectious cause of URTI to be confirmed by Respiratory Pathogens Panel.
• Has body weight more than 55 kg for male and 50 kg for female and body mass index between 18 and 32 kg/m2, inclusive.
• Has no declared medical history of hypertension and cardiovascular disease in the last 10 years.
• At screening, has stable vital signs in the following ranges (after 5 minutes of

rest):

• SBP =90 and =140 mmHg
• DBP =50 and =90 mmHg
• HR =45 and =100 beats per minute (bpm)
• Is a nonsmoker within the previous 2 months (calculated from first dosing) and does not use tobacco-containing products.

Exclusion Criteria:

• Has a stated history of clinically significant gastrointestinal, renal, hepatic, neurologic, hematologic, endocrine, oncologic, pulmonary, immunologic, psychiatric, or cardiovascular disease or any other condition which, in the opinion of the Investigator, would jeopardize the safety of the subject or impact the validity of the study results.
• Has current or past history of clinically significant asthma or angioedema.
• Has prior nasal fractures, severe nasal injuries or history of nasal disorders that could interfere with nasal spray administration.
• Has any clinically significant medical condition or physical exam (PE) finding as deemed inappropriate by the Investigator.
• Has abnormal cardiovascular exam at screening including any prior history of myocardial infarction or clinically significant abnormal ECG.
• Subject reports they have had significant traumatic injury, major surgery or open biopsy within 30 days prior to study screening.
• Subject reports they have donated blood including platelets or plasma only or had an acute loss of blood (>50 mL) during the 30 days before study drug administration or intends to donate blood or blood products within 30 days after the completion of the study.
• Has a history (within 12 months before screening) of drug use, or has a positive test for drugs of abuse at screening or upon admittance to the study center, or has a stated history of alcohol abuse.
• Has been on an abnormal diet during the four (4) weeks from Day 0. 10. Has participated in a clinical trial within 30 days prior to the first dose of study drug.

11. Has had treatment with any adrenaline or noradrenaline containing products within 7 days of Day 0.

12. Has inadequate or difficult venous access that may jeopardize the quality or timing of the PK samples.

Related Conditions & MeSH terms

• Communicable Diseases
• Infections
• Respiratory Tract Infections
• Upper Respiratory Tract Infection

Intervention

Drug:
• ARS-1 with URTI
ARS-1
• ARS-1 without URTI
ARS-1 without URTI

Locations

Country	Name	City	State
Australia	Anthony McGirr	Brookvale	New South Wales

Sponsors (1)

Lead Sponsor	Collaborator
ARS Pharmaceuticals, Inc.

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To evaluate the bioavailability (Cmax) of ARS-1 after intranasal administration	Blood samples will be collected to measure plasma concentrations of adrenaline	Day -1 to Day 30
Primary	To evaluate the bioavailability (AUC0-t) of ARS-1 after intranasal administration	Blood samples will be collected to measure plasma concentrations of adrenaline	Day -1 to Day 30
Primary	To evaluate the bioavailability (tmax) of ARS-1 after intranasal administration	Blood samples will be collected to measure plasma concentrations of adrenaline	Day -1 to Day 30